Nightfood Holdings (OTCQB: NGTF), doing business as TechForce Robotics, announced a joint development, manufacturing and licensing agreement with Oncotelic Therapeutics (OTCQB: OTLC) to co-develop AI-enhanced, GMP-compliant robotic systems for pharmaceutical manufacturing and laboratory automation. The collaboration combines TechForce’s robotics engineering with Oncotelic’s AI-driven pharmaceutical technologies to target improved efficiency, compliance and scalability in biopharma production, marking TechForce’s expansion into regulated healthcare markets while leveraging Oncotelic CEO Dr. Vuong Trieu’s experience in oncology, drug development and AI-enabled innovation.
NOTE TO INVESTORS: The latest news and updates relating to NGTF are available in the company’s newsroom at http://nnw.fm/NGTF
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer